Method of using Dantrolene, a FDA-approved drug, currently used for treatment of muscular skeletal dysfunction, to treat T-lymphocyte mediated disorders (autoimmune diseases and chronic graft versus host disease) in humans and animals.
T lymphocytes (T cells) play a critical role in regulation of immune system function. They control cell-mediated immunity, provide defense against infectious microbes, recognize and eliminate foreign substances, and act as surveillance for cancer cells. T cells, however, are also the primary causes of inflammatory responses in patients with autoimmune disorders and graft rejection in organ transplant patients.
Researchers at the University of California, Davis have discovered that Dantrolene, a FDA approved drug currently used for the treatment of muscular skeletal dysfunctions, significantly suppresses CD4+ T cell functions such as proliferation and cytokine production. By targeting T cells, Dantrolene can effectively reduce inflammation-induced tissue damage. Furthermore, this drug can effectively reduce graft rejection.
|United States Of America||Issued Patent||9,301,947||04/05/2016||2009-313|
|United States Of America||Issued Patent||8,664,251||03/04/2014||2009-313|